CORT Share Price Performance
US$37.36
-13.70 (-26.83%)
60.7% undervalued intrinsic discount
US$95.00
Fair Value
Price US$37.36
AnalystLowTarget US$95.00
AnalystConsensusTarget US$91.00
AnalystHighTarget US$121.00
Fair ValueUS$95.00
Share Pricen/a
Corcept Therapeutics Incorporated Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 124 Fair Values set on narratives written by author
CORT Community Narratives
AN
Fair Value US$95 60.7% undervalued intrinsic discount
Cortisol Modulation Risks May Overshadow Oncology Ambitions Yet Long-Term Prospects Remain Appealing
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value US$91 58.9% undervalued intrinsic discount
Patient Screening And Regulatory Approvals Will Unlock Global Markets
0users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
AN
Fair Value US$121 69.1% undervalued intrinsic discount
Upcoming Hypercortisolism And Oncology Approvals Will Transform This Cortisol Modulation Leader
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Corcept and its fair value according my DCF valuation
Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato.Read more
63
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Patient Screening And Regulatory Approvals Will Unlock Global Markets
Key Takeaways Expanding disease awareness, anticipated drug approvals, and enhanced commercial operations are set to propel revenue growth and decrease reliance on a single product. Favorable demographic trends and proven regulatory execution support ongoing market and earnings expansion for the company.Read more
751
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
AN
US$91
58.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
29% p.a.
Profit Margin
37.06%
Future PE
19.64x
Price in 2029
US$111.08
Upcoming Hypercortisolism And Oncology Approvals Will Transform This Cortisol Modulation Leader
Catalysts About Corcept Therapeutics Corcept Therapeutics develops selective cortisol modulators to treat serious endocrine, metabolic and oncologic diseases. What are the underlying business or industry changes driving this perspective?Read more
38
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$121
69.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
37.51% p.a.
Profit Margin
36.75%
Future PE
21.79x
Price in 2029
US$148.05
Cortisol Modulation Risks May Overshadow Oncology Ambitions Yet Long-Term Prospects Remain Appealing
Catalysts About Corcept Therapeutics Corcept Therapeutics develops proprietary selective cortisol modulators to treat endocrine, oncologic, neurologic and metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
48
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$95
60.7% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
33.35% p.a.
Profit Margin
31.78%
Future PE
21.69x
Price in 2028
US$116.24
Trending Discussion
Recently Updated Narratives
GI
Corcept and its fair value according my DCF valuation
Fair Value: US$63.53 41.2% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside
Fair Value: US$91 58.9% undervalued intrinsic discount
55 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Upcoming Hypercortisolism And Oncology Approvals Will Transform This Cortisol Modulation Leader
Fair Value: US$121 69.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Corcept Therapeutics Incorporated Key Details
About CORT
- Founded
- 1998
- Employees
- 500
- CEO
- WebsiteView website
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
